Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer

Duncan C. Gilbert; Eva Serup-Hansen; Dorte Linnemann; Estrid Høgdall; Charles Bailey; Jeff Summers; Hanne Havsteen; Gareth J. Thomas

doi:10.1038/bjc.2015.448

Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer

Duncan C. Gilbert^*, Eva Serup-Hansen, Dorte Linnemann, Estrid Høgdall, Charles Bailey, Jeff Summers, Hanne Havsteen, Gareth J. Thomas

^*Corresponding author for this work

43 Citations (Scopus)

Abstract

Background: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV- patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group.

Methods: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs).

Results: Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006).

Conclusions: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.

Original language	English
Journal	British Journal of Cancer
Volume	114
Pages (from-to)	134-137
Number of pages	4
ISSN	0007-0920
DOIs	https://doi.org/10.1038/bjc.2015.448
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2015.448Licence: CC BY-NC-SA

Cite this

@article{3671c9189b41478f84c83b0688f77384,

title = "Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer",

abstract = "Background: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV- patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group.Methods: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs).Results: Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006).Conclusions: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.",

author = "Gilbert, {Duncan C.} and Eva Serup-Hansen and Dorte Linnemann and Estrid H{\o}gdall and Charles Bailey and Jeff Summers and Hanne Havsteen and Thomas, {Gareth J.}",

year = "2016",

doi = "10.1038/bjc.2015.448",

language = "English",

volume = "114",

pages = "134--137",

journal = "The British journal of cancer. Supplement",

issn = "0007-0920",

publisher = "nature publishing group",

}

TY - JOUR

T1 - Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer

AU - Gilbert, Duncan C.

AU - Serup-Hansen, Eva

AU - Linnemann, Dorte

AU - Høgdall, Estrid

AU - Bailey, Charles

AU - Summers, Jeff

AU - Havsteen, Hanne

AU - Thomas, Gareth J.

PY - 2016

Y1 - 2016

N2 - Background: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV- patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group.Methods: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs).Results: Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006).Conclusions: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.

AB - Background: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV- patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group.Methods: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs).Results: Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006).Conclusions: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.

U2 - 10.1038/bjc.2015.448

DO - 10.1038/bjc.2015.448

M3 - Letter

C2 - 26730577

AN - SCOPUS:84955206917

SN - 0007-0920

VL - 114

SP - 134

EP - 137

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

ER -

Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this